BiotechTube

IBIO-600 + Placebo

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight , Obesity

Conditions

Overweight , Obesity

Trial Timeline

Apr 1, 2026 → May 1, 2027

NCT ID
NCT07487376

About IBIO-600 + Placebo

IBIO-600 + Placebo is a phase 1 stage product being developed by iBio for Overweight , Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07487376. Target conditions include Overweight , Obesity.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07487376Phase 1Recruiting

Competing Products

20 competing products in Overweight , Obesity

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
49
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
33
LY3305677 + PlaceboEli LillyPhase 1
33
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
33
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
33
Tirzepatide + AcetaminophenEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY3437943 + PlaceboEli LillyPhase 1
33
LY3502970 + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
LY3541105 + PlaceboEli LillyPhase 1
33
Retatrutide + PlaceboEli LillyPhase 2
52
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
33
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
52

Other Products from iBio

PHI-101 administrationPhase 1
25
PHI-101Phase 1
25